To add large-scale lyophilization and sterile fill-finish capabilities to its clinical and commercial manufacturing offering.
Closes investment from Oak HC/FT to accelerate growth; Jenn Adams named chief executive officer.
Cell and gene therapies represent the new wave of innovation in the life sciences industry